Oncologist Intervention for Fear of Cancer Recurrence in Breast, Ovarian, and Prostate Cancer
Clinician-led intervention to address fear of cancer recurrence (CIFeR)
Treatment Study
Summary
Study start date: June 14, 2024
Actual date on which the first participant was enrolled.This study aims to help people who have been treated for breast, ovarian, or prostate cancer and are experiencing a fear of their cancer coming back, known as Fear of Cancer Recurrence (FCR). The study involves oncologists from several hospitals who will receive special training to provide their patients with a brief intervention designed to address FCR. This is important because fear of cancer coming back can significantly affect a person's quality of life and mental health. By teaching oncologists how to better support their patients' emotional needs, this study hopes to improve the mental well-being of cancer survivors. Participants in the study are cancer patients who have completed their primary treatment within the last three months and express a significant fear of recurrence. They will complete several questionnaires before and after their consultation with an oncologist to measure changes in their fear levels, anxiety, depression, and overall quality of life. The oncologists will deliver a structured intervention during the consultation, which includes providing reassurance, information on recurrence risk, and strategies to manage worry. The effectiveness of this intervention is assessed by comparing the patient's fear levels before and after the intervention, and the oncologists' experiences and confidence in delivering the intervention are also evaluated.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.300 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Are ≥ 18 years old * Have completed their primary treatment, i.e., surgery, adjuvant chemotherapy, and/or radiotherapy, for breast, ovarian, prostate, or lung cancer at the participating departments between three weeks and three months previously. * Score \>= 13 on the FCRI-SF Exclusion Criteria: \-
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location